Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
This is a noninterventional study in an adult population of men and women with a diagnosis of MF or PV. The study will enroll patients with a diagnosis of PV or MF. Basic demographic information and disease history will be collected. Participants will also be subjected to a physical examination. Viable frozen mononuclear cells (MNCs) will be collected from participants via blood draw (patients with MF) or therapeutic phlebotomy (patients with PV). In addition to samples collected from patients with PV and MF, banked MNCs from peripheral blood or bone marrow may also be included in the study. CD34+ cells will be isolated from MNCs from patients with PV and MF and the banked samples. Cryopreserved CD34+ cells obtained from the bone marrow of healthy participants will be purchased from a third party. All CD34+ cell specimens (from patients, banked specimens, and healthy participants) will undergo epigenetic and gene expression analyses. For each disease state (MF and PV), the epigenomes of patients and healthy participants will be compared with each other in order to identify potential novel gene control targets.